Clinical Management in Multiple Sclerosis

This review aims to provide a comprehensive overview of the main types, subtypes, clinical manifestations, and current therapeutic strategies for multiple sclerosis, emphasizing recent advancements and clinical challenges. Multiple Sclerosis (MS) is a demyelinating, chronic, autoimmune, and inflammatory disease that affects the Central Nervous System (CNS). Its classification has the following subtypes: Relapsing-Remitting (RRMS), Secondary-Progressive (SPMS), and Primary-Progressive (PPMS), including rarer subtypes such as Clinically Isolated Syndrome (CIS), Radiologically Isolated Syndrome (RIS), Balo’s Concentric Sclerosis (BCS), Schilder’s Disease (SD), and Progressive-Relapsing MS (PRMS). This article divides the various treatments for MS into the following three categories: acute relapse management, symptomatic treatments, and Disease-Modifying Treatments (DMTs). The latter represents revolutionary research in MS, since they are the drugs considered as the best treatment alternatives for this disease.

Authors

Institutions

Publication Details

Journal
Neuroglia
Published
2025-02-05
DOI
https://doi.org/10.3390/neuroglia6010006
Citations
6
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
8.83
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical Management in Multiple Sclerosis

Kenneth Rodriguez-Lopez, Rodolfo Daniel Ávila‐Avilés, Ana Victoria Arredondo-Robles
6 citations
Neuroglia
Multiple Sclerosis Research Studies
8.83
article

Clinical Management in Multiple Sclerosis

Kenneth Rodriguez-Lopez, Rodolfo Daniel Ávila‐Avilés, Ana Victoria Arredondo-Robles
article en
6 citations

Abstract

This review aims to provide a comprehensive overview of the main types, subtypes, clinical manifestations, and current therapeutic strategies for multiple sclerosis, emphasizing recent advancements and clinical challenges. Multiple Sclerosis (MS) is a demyelinating, chronic, autoimmune, and inflammatory disease that affects the Central Nervous System (CNS). Its classification has the following subtypes: Relapsing-Remitting (RRMS), Secondary-Progressive (SPMS), and Primary-Progressive (PPMS), including rarer subtypes such as Clinically Isolated Syndrome (CIS), Radiologically Isolated Syndrome (RIS), Balo’s Concentric Sclerosis (BCS), Schilder’s Disease (SD), and Progressive-Relapsing MS (PRMS). This article divides the various treatments for MS into the following three categories: acute relapse management, symptomatic treatments, and Disease-Modifying Treatments (DMTs). The latter represents revolutionary research in MS, since they are the drugs considered as the best treatment alternatives for this disease.

NeurogliaVol. 6(1)
Universidad Autónoma del Estado de México (MX), Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (MX)
Openalex Percentile: Top 2%
Multiple Sclerosis Research Studies
8.83
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Clinical Management in Multiple Sclerosis — Kenneth Rodriguez-Lopez, Rodolfo Daniel Ávila‐Avilés, et al. · Neuroglia (2025) | TGRS Research Map | TGRS